BRAF and melanoma: For example, in a BRAFV600E-mutant melanoma model the development of resistance to sequential treatment with the RAFi Vemurafenib, the MEKi Trametinib and the ERKi SCH772984 was shown to be due to progressive increase in BRAF copy number [32].